Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)

The Breast · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles